According to the new market research report "Intraoperative Radiation Therapy Market by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) - Global Forecasts to 2025", published by MarketsandMarkets™, the Intraoperative radiation therapy products market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period.
Browse in-depth TOC on "Intraoperative Radiation Therapy Market"
77 – Tables
33 – Figures
159 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083
The technological advancements such as the introduction of mobile IORT system, rising incidence of cancer, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy products market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.
Key Market Players
The competitive landscape includes the analysis of the key growth strategies adopted by major players between 2017–2020 to expand their global presence and increase their shares in the global intraoperative radiation therapy market. The key growth strategies adopted by the top players in the market are product launches and approvals, agreements, partnerships, mergers and acquisitions, and expansions. Prominent players in the intraoperative radiation therapy market include ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems Inc. (US), Xstrahl Medical (UK), DOSIsoft SA (France), Huiheng Medical (China), Sun Nuclear Corporation (US), and Theragenics Corporation (US).
ZEISS is among the pioneer companies that combined surgery with radiotherapy to develop and introduce intraoperative radiation therapy to the cancer treatment field. The flagship product of the company, INTRABEAM, is one of the most widely used IORT products across the globe. INTRABEAM is a revolutionary, intraoperative form of radiation therapy for early-stage breast cancers. It allows radiation treatment and breast-conserving surgery to be performed simultaneously. As a result, the need for several weeks of external radiation therapy following surgery can often be minimized or eliminated. The strong foothold of the company in the intraoperative radiation therapy market can be attributed to its wide geographic reach. ZEISS has a direct presence in almost 50 countries and more than 30 production sites and 25 R&D facilities. ZEISS has a sound custom services support set up, which helps it to strengthen its customer relationships and presence in the market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083
iCAD, Inc. is a major player in the intraoperative radiation therapy market. The company offers a wide range of IORT products, including electronic brachytherapy products, different types of applicators, and accessories. In the last three years, the company has significantly invested in R&D activities to launch advanced products in the market. In 2019, the company invested USD 9.4 million in R&D.
North America to dominate the intraoperative radiation therapy market during the forecast period
The Intraoperative radiation therapy products market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North American region is expected to account for the largest share of the market in 2019. The growth in this market is mainly attributed to the increasing healthcare expenditure in the region, technological advancements, and high adoption of IORT products owing to the increasing incidence of cancer.
Recent Developments
- Elekta AB launched Geneva, a universal gynecological applicator for brachytherapy.
- Varian acquired Cancer Treatment Services International (CTSI), a US-based oncology solutions division that provides cancer care professional services to healthcare providers worldwide. The acquisition expanded Varian’s access to technology-driven cancer care .
- Varian launched the Bravos afterloader system for high-dose-rate (HDR) brachytherapy treatments
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245000083
